IKT icon

Inhibikase Therapeutics
IKT

Overview Fund Activity

22 hedge funds and large institutions have $2.49M invested in Inhibikase Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
8
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
AC
1
Antara Capital
New York
$299K
2
Koshinski Asset Management
2
Koshinski Asset Management
Illinois
$49K
3
Renaissance Technologies
3
Renaissance Technologies
New York
$165K
4
William Blair & Company
4
William Blair & Company
Illinois
$19K
5
TRCT
5
Tower Research Capital (TRC)
New York
$12K

Top Sellers

1
KC
1
Kepos Capital
New York
$0
2
LCM
2
Lynwood Capital Management
Ontario, Canada
$0
3
SM
3
Sabby Management
Florida
$0
4
ACM
4
ACT Capital Management
Pennsylvania
$696K
5
BlackRock
5
BlackRock
New York
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
UBS Group
26
UBS Group
Switzerland
– -$8K -852 Closed
1
2